摘要
【目的】探讨膜联蛋白A2(Annexin A2)、高迁移率族蛋白B1(HMGB1)的表达与脑胶质瘤病理学分级、癫痫发作的关系.【方法】选取本院病理中心收集的80例脑胶质瘤组织标本(观察组)、40例脑外伤患者手术组织(对照组).采用免疫组化染色技术检测两组标本中Annexin A2、HMGB1蛋白表达情况,分析不同组织学分级、癫痫发作频率、癫痫发作时间的患者Annexin A2、HMGB1蛋白表达的差异.【结果】观察组Annexin A2蛋白、HMGB1蛋白阳性表达率均显著高于对照组,差异均有统计学意义(χ^2=22.097,P<0.05;χ^2=26.167,P<0.05).观察组患者不同病理分级Annexin A2蛋白阳性表达率比较,差异有统计学意义(P<0.05);不同癫痫发作频率及癫痫持续时间的患者Annexin A2蛋白阳性表达率比较,差异无统计学意义(P>0.05).观察组不同病理分级、不同癫痫发作频率及癫痫持续时间的患者HMGB1蛋白阳性表达率比较,差异有统计学意义(P<0.05).【结论】在脑胶质瘤患者病灶组织中Annexin A2、HMGB1蛋白的阳性表达率明显上升;Annexin A2蛋白、H M GB1蛋白的过表达与脑胶质瘤的恶性程度增加及癫痫发作情况有关.
【Objective】To investigate the relationship between the expression of annexin A2 and HMGB1 and the pathological grade of gliomas and seizures.【Methods】Eighty glioma tissue samples(observation group)and 40 surgical tissues(control group)were collected from the pathology center of our hospital.The expression of annexin A2 and HMGB1 protein in the two groups were detected by immunohistochemical staining,and the differences of annexin A2 and HMGB1 protein expression in patients with different histological grades,seizure frequency and seizure time were analyzed.【Results】The positive rates of annexin A2 protein and HMGB1 protein in the observation group were significantly higher than those in the control group(χ^2=22.097,P<0.05;χ^2=26.167,P<0.05).There was no significant difference in the positive expression rate of annexin A 2 protein among the patients with different pathological grades in the observation group(P<0.05).The positive expression rate of HMGB1 protein in different pathological grades,seizure frequency and duration of epilepsy in the observation group was statistically significant(P<0.05).【Conclusion】The positive expression rate of annexin A2 and HMGB1 protein in the lesions of glioma patients increased significantly;overexpression of annexin A2 protein and HMGB1 protein is related to the increase of malignant degree of glioma and seizure.
作者
梅晋
余露
王斌
曹长军
MEI Jin;YU Lu;WANG Bin(Huangmei people’s Hospital,huan gmei 435500)
出处
《医学临床研究》
CAS
2020年第6期901-903,共3页
Journal of Clinical Research
